Folgen
Marcel A. Müller
Marcel A. Müller
Staff Scientist, Institute of Virology, Charité Universitätsmedizin Berlin
Bestätigte E-Mail-Adresse bei charite.de
Titel
Zitiert von
Zitiert von
Jahr
SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor
M Hoffmann, H Kleine-Weber, S Schroeder, N Krüger, T Herrler, ...
cell 181 (2), 271-280. e8, 2020
149652020
Virological assessment of hospitalized patients with COVID-2019
R Wölfel, VM Corman, W Guggemos, M Seilmaier, S Zange, MA Müller, ...
Nature 581 (7809), 465-469, 2020
61372020
Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
VS Raj, H Mou, SL Smits, DHW Dekkers, MA Müller, R Dijkman, D Muth, ...
Nature 495 (7440), 251-254, 2013
19862013
Severe acute respiratory syndrome coronavirus 2− specific antibody responses in coronavirus disease patients
NMA Okba, MA Müller, W Li, C Wang, CH GeurtsvanKessel, VM Corman, ...
Emerging infectious diseases 26 (7), 1478, 2020
13352020
Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response
I Glowacka, S Bertram, MA Müller, P Allen, E Soilleux, S Pfefferle, I Steffen, ...
Journal of virology 85 (9), 4122-4134, 2011
9552011
SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19
J Braun, L Loyal, M Frentsch, D Wendisch, P Georg, F Kurth, ...
Nature 587 (7833), 270-274, 2020
8732020
Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study
CBEM Reusken, BL Haagmans, MA Müller, C Gutierrez, GJ Godeke, ...
The Lancet infectious diseases 13 (10), 859-866, 2013
8082013
The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells
M Hoffmann, H Kleine-Weber, N Krüger, M Müller, C Drosten, ...
BioRxiv, 2020
7602020
Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction
VM Corman, I Eckerle, T Bleicker, A Zaki, O Landt, M Eschbach-Bludau, ...
Eurosurveillance 17 (39), 20285, 2012
6892012
Bats host major mammalian paramyxoviruses
JF Drexler, VM Corman, MA Müller, GD Maganga, P Vallo, T Binger, ...
Nature communications 3 (1), 1-13, 2012
5862012
Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection
C Drosten, M Seilmaier, VM Corman, W Hartmann, G Scheible, S Sack, ...
The Lancet infectious diseases 13 (9), 745-751, 2013
4682013
Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections
VM Corman, MA Müller, U Costabel, J Timm, T Binger, B Meyer, P Kreher, ...
Eurosurveillance 17 (49), 20334, 2012
4252012
Transmission of MERS-coronavirus in household contacts
C Drosten, B Meyer, MA Müller, VM Corman, M Al-Masri, R Hossain, ...
New England Journal of Medicine 371 (9), 828-835, 2014
4222014
Serological assays for emerging coronaviruses: challenges and pitfalls
B Meyer, C Drosten, MA Müller
Virus research 194, 175-183, 2014
4162014
Genomic characterization of severe acute respiratory syndrome-related coronavirus in European bats and classification of coronaviruses based on partial RNA-dependent RNA …
JF Drexler, F Gloza-Rausch, J Glende, VM Corman, D Muth, M Goettsche, ...
Journal of virology 84 (21), 11336-11349, 2010
4002010
Human infection with MERS coronavirus after exposure to infected camels, Saudi Arabia, 2013
ZA Memish, M Cotten, B Meyer, SJ Watson, AJ Alsahafi, AA Al Rabeeah, ...
Emerging infectious diseases 20 (6), 1012, 2014
3992014
Viral shedding and antibody response in 37 patients with Middle East respiratory syndrome coronavirus infection
VM Corman, AM Albarrak, AS Omrani, MM Albarrak, ME Farah, M Almasri, ...
Clinical Infectious Diseases 62 (4), 477-483, 2016
3972016
The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors
S Pfefferle, J Schöpf, M Kögl, CC Friedel, MA Müller, J Carbajo-Lozoya, ...
PLoS pathogens 7 (10), e1002331, 2011
3902011
Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19
M Hoffmann, S Schroeder, H Kleine-Weber, MA Müller, C Drosten, ...
Antimicrobial agents and chemotherapy 64 (6), e00754-20, 2020
3802020
Clinical presentation and virological assessment of hospitalized cases of coronavirus disease 2019 in a travel-associated transmission cluster
R Woelfel, VM Corman, W Guggemos, M Seilmaier, S Zange, MA Mueller, ...
MedRxiv 2020, 2020
3412020
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20